

Hanne Bak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1955059/publications.pdf>

Version: 2024-02-01

9
papers

371
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

389
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergism with the Coactivator OBF-1 (OCA-B, BOB-1) Is Mediated by a Specific POU Dimer Configuration. <i>Cell</i> , 2000, 103, 853-864.	28.9	134
2	Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. <i>MABs</i> , 2016, 8, 828-838.	5.2	77
3	Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification. <i>Biotechnology and Bioengineering</i> , 2020, 117, 3199-3211.	3.3	39
4	Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development. <i>MABs</i> , 2021, 13, 1955811.	5.2	29
5	Assessment of quality attributes for adeno-associated viral vectors. <i>Biotechnology and Bioengineering</i> , 2021, 118, 4186-4203.	3.3	22
6	Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity. <i>Biotechnology Progress</i> , 2018, 34, 650-658.	2.6	21
7	Putative Phospholipase B-Like 2 is Not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2710-2718.	3.3	21
8	Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases. <i>Pharmaceutical Research</i> , 2022, 39, 75-87.	3.5	16
9	A general evidence-based sequence variant control limit for recombinant therapeutic protein development. <i>MABs</i> , 2020, 12, 1791399.	5.2	11